by glycosylation to give 3′-deuteriothymidine in 19% overall
yield after 11 synthetic steps.9
Scheme 2. Synthesis of 3′-Deuterated Cytidine Derivative 6
We describe here the stereospecific synthesis of 2′-deoxy-
3′-deutero pyrimidine nucleosides in high yields and their
incorporation into DNA. This route is efficient and suitable
for large-scale preparation of pyrimidine nucleosides 1a and
1b (Scheme 1). The synthetic strategy utilizes the free 5′-
Scheme 1. Syntheses of 1a and 1b
from the â-face (Figure S1b) to yield a mixture of 1-(2′-
deoxy-3′-deutero-â-D-ribofuranosyl)thymine (1a) and 1-(2′-
deoxy-3′-deutero-â-D-xylofuranosyl)thymine (2a) (95:5 ratio
by 1H NMR), readily separated by column chromatography
or HPLC. Deuterium incorporation at the 3′-position of the
sugar ring was evident by the absence of the signal at 4.27
ppm from its 1H NMR spectrum. The 5′-hydroxyl group of
1a was subsequently protected as a dimethoxytrityl (DMT)
ether and the 3′-hydroxyl group phosphitylated to yield
phosphoramidite 7a, which was incorporated into DNA using
standard phosphoramidite chemistry.
The same strategy that was used to prepare 3′-deutero
thymidine was applied in the synthesis of 2′-deoxy-3′-deutero
cytidine, the synthesis of which has not been reported.
Previous attempts to prepare the keto derivative by oxidation
of 4-N-acetyl-2′-deoxy-5′-O-trityl cytidine with CrO3/pyri-
dine/Ac2O resulted in â-elimination and formation of 4,5-
dihydro-5-trityloxymethylfuran-4-one.7 In contrast, oxidation
of 4-N-benzoyl-2′-deoxy-5′-O-(dimethoxytrityl)cytidine14 with
PDC afforded the corresponding keto-derivative 5 in 75%
hydroxyl groups of 3′-keto thymidine and 2′-deoxy-3′-keto
uridine to direct reduction to the â-face of the 3′-ketone
through coordination with sodium triacetoxyborodeuteride.10,11
Selective oxidation of the 3′-hydroxyl group required the use
of a 5′-hydroxyl protecting group that could be removed after
oxidation without elimination of the nucleobase, because the
free 5′-hydroxyl group is required for directing the reducing
agent to the â-face of the ketone. Since the reductions are
performed under acidic conditions, we chose the acid-labile
dimethoxytrityl protecting group.
Oxidation of 5′-dimethoxytrityl thymidine was accom-
plished with pyridinium dichromate (PDC), resulting in 81%
yield of the corresponding 3′-keto thymidine (4a).12,13
Following oxidation, ketone 4a was deprotected and reduced
by treatment with sodium triacetoxyborodeuteride, formed
in situ from sodium borodeuteride and acetic acid, in a two-
step, one-pot procedure to give 1a in 85% yield. Figure S1
in Supporting Information illustrates the effect of sodium
triacetoxyborodeuteride on the change in stereoselectivity of
the reduction, when compared to sodium borodeuteride. The
sodium borodeuteride reduction preferentially reduced the
ketone from the R-face (Figure S1a),7 whereas sodium
triacetoxyborodeuteride delivered the hydride predominantly
1
yield, which was characterized by H NMR and HRMS.
However, the 3′-keto derivative of 2′-deoxy cytidine (5) was
much more unstable under the conditions of deprotection/
reduction than the corresponding thymidine derivative 4a.
This is presumably due to the ease of protonation of cytidine
under the acidic conditions, which accelerates â-elimination
of the nucleobase. As a result, the expected product 6 was
obtained in only 10% yield.
These results led us to investigate an alternative synthetic
route, utilizing the known conversion of a thymine base to
a methylcytosine through the corresponding triazole deriva-
tive (Scheme 3).15,16 2′-Deoxy-3′-keto uridine (4b) was
synthesized by the oxidation of 2′-deoxy-5′-O-dimethoxytri-
tyl uridine (3b) with PDC in 80% yield. Subsequent treatment
with triacetoxyborodeuteride resulted in a mixture of 1-(2′-
deoxy-3′-deutero-â-D-ribofuranosyl)uracil (1b) and 1-(2′-
deoxy-3′-deutero-â-D-xylofuranosyl)uracil (2b) (94:6 ratio
by 1H NMR). Compound 1b was isolated in 83% yield and
converted to the protected phosphoramidite 7b, from which
(9) Chen, T.; Greenberg, M. M. Tetrahedron Lett. 1998, 39, 1103-1106.
(10) Hoveyda, A. H.; Evans, D. A.; Fu, G. C. Chem. ReV. 1993, 93,
1307-1370.
(11) Robins, M. J.; Sarker, S.; Samano, V.; Wnuk, S. F. Tetrahedron
1997, 53, 447-456.
(12) Froehlich, M. L.; Swartling, D. J.; Lind, R. E.; Mott, A. W.;
Bergstrom, D. E. Nucleosides Nucleotides 1989, 8, 1529-1535.
(13) Svendsen, M. L.; Wengel, J.; Kirpekar, F.; Roepstorff, P. Tetrahe-
dron 1993, 49, 11341-11352.
(14) Ti, G. S.; Gaffney, B. L.; Jones, R. A. J. Am. Chem. Soc. 1982,
104, 1316-1319.
(15) Cowart, M.; Gibson, K. J.; Allen, D. J.; Benkovic, S. J. Biochemistry
1989, 28, 1975-1983.
(16) Xu, Y.-Z.; Zheng, Q.; Swann, P. F. J. Org. Chem. 1992, 57, 3839-
3845.
918
Org. Lett., Vol. 5, No. 6, 2003